Myositis Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
November 13, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Myositis Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses...
Global Automotive OBD Dongle Markets to 2027: Rising Adoption of Usage-based Insurance (UBI) Models Driving the Industry
July 28, 2023 06:08 ET
|
Research and Markets
Dublin, July 28, 2023 (GLOBE NEWSWIRE) -- The "Global Automotive OBD Dongle Market 2023-2027" report has been added to ResearchAndMarkets.com's offering. Automotive OBD Dongle Market to Witness...
ROSEN, A LEADING LAW FIRM, Encourages Orphazyme A/S Investors With Losses Over $100K to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
August 03, 2021 16:04 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
Biotalys Nominates Catherine Moukheibir to its Board of Directors
June 10, 2021 02:00 ET
|
Biotalys
Ghent, BELGIUM, June 10, 2021 (GLOBE NEWSWIRE) -- Biotalys Nominates Catherine Moukheibir to its Board of Directors Highly respected finance and life sciences professional to chair company’s Audit...
Automated/Autonomous Parking Market Report 2020: Concepts & Technologies, Technology Providers, Application and Trends
September 08, 2020 04:43 ET
|
Research and Markets
Dublin, Sept. 08, 2020 (GLOBE NEWSWIRE) -- The "Automated/Autonomous Parking Industry Report, 2019-2020" report has been added to ResearchAndMarkets.com's offering. Why is the installation rate of...
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
July 21, 2019 06:03 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 18/2019Company Registration No. 32266355 ...
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis
July 18, 2019 01:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 17/2019 ...
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
June 07, 2019 00:56 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme announces enrollment of first patient in Phase III clinical trial of arimoclomol for ALS
August 10, 2018 12:19 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Global Metabolism Drugs Market to Surpass US$ 9.9 Billion by 2026 – Coherent Market Insights
July 16, 2018 10:00 ET
|
Coherent Market Insights
Seattle, July 16, 2018 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global metabolism drugs market was valued at US$ 5,765.3 million in 2017 and is projected to exhibit a CAGR of...